56 for mI/Cr ratio, it was possible to differentiate oligodendrog

56 for mI/Cr ratio, it was possible to differentiate oligodendrogliomas from astrocytomas with a sensitivity of 72.4% and specificity of 76.4%. These results suggest that

mI/Cr might aid in distinguishing oligodendrogliomas from astrocytomas. J Neuroimaging 2010;20:3-8. “
“Botulinum toxin (BTX) treatment can relieve focal arm spasticity after stroke, presumably through dynamic changes at multiple levels of the motor system, including the cerebral cortex. However, the neuroanatomical correlate of BTX spasticity relief is not known and should be reflected in changes of cortical activation during motor tasks assessed using repeated functional magnetic resonance imaging (fMRI). Four patients (2 males, 2 females, Ixazomib concentration mean age 25.5 years) with hemiplegia ABT-263 in vitro and distal arm spasticity after chronic ischemic stroke sparing the motor cortex were studied. fMRI during mental movement simulation of the impaired hand was performed in 2 sessions before and 4 weeks after BTX treatment. The change in arm spasticity was assessed using the modified Ashworth scale (MAS). BTX treatment significantly decreased arm spasticity

across the group (mean MAS change 2.1). Whereas fMRI during imagined movement pre-BTX treatment showed extensive bilateral network of active areas, post-BTX activation was confined to the midline and contralateral sensorimotor cortices. The pre- > post-BTX contrast revealed a significant decrease in activation of the posterior cingulate/precuneus region after BTX treatment. This small study suggests that structures outside the classical motor system, such as the posterior cingulate/precuneus region, may be associated with the relief of poststroke arm spasticity.

“Symptomatic thromboembolic events are the most common complications associated with aneurysm coiling, and carotid and intracranial stenting. 上海皓元医药股份有限公司 Our objective is to assess the effect of aspirin (ASA) and clopidogrel dose and duration on platelet inhibition using a point of care assay in neurointerventional (NI) suite. The dose, duration, and point of care platelet function assay data for clopidogrel and aspirin therapy were prospectively collected between February 2006 and November 2007. Inadequate platelet inhibition for ASA was defined as ≥550 ASA reaction units (ARU), and for clopidogrel was defined as ≤50% inhibition of the P2Y12/ADP receptor We collected data from 216 consecutive patients. Inadequate platelet inhibition was noted in 13% of patients on aspirin and 66% of patients on clopidogrel (P-value < .0001). Patients taking clopidogrel 75 mg for ≥7 days, 300 mg for 24 hours, and 600 mg same day load had a mean P2Y12/ADP inhibition of 45%, 35% (P-value = .09), and 16%, respectively (P-value = .005). Premedication with clopidogrel, in contrast to aspirin, does not achieve adequate platelet inhibition in about two-third of the patients. Same day antiplatelet loading may be insufficient to achieve adequate platelet inhibition and should be avoided if clinically feasible.

Leave a Reply

Your email address will not be published. Required fields are marked *


You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>